{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:41:16Z","timestamp":1786372876590,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Natural Science Fund","award":["81102015"],"award-info":[{"award-number":["81102015"]}]},{"name":"National Natural Science Fund","award":["81301858"],"award-info":[{"award-number":["81301858"]}]},{"name":"Special Fund for Technological Innovation of Shanghai Jiaotong University","award":["YG2012MS46"],"award-info":[{"award-number":["YG2012MS46"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00432-016-2127-2","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T08:53:25Z","timestamp":1456995205000},"page":"1315-1323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial"],"prefix":"10.1007","volume":"142","author":[{"given":"Ying-Chun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"2127_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1479-5876-8-129","volume":"7","author":"G Bonanno","year":"2010","unstructured":"Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D et al (2010) Thymoglobulin, interferon- \u03b3 and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med 7:129\u2013143","journal-title":"J Transl Med"},{"issue":"9","key":"2127_CR2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00262-014-1566-3","volume":"63","author":"MJ Chung","year":"2014","unstructured":"Chung MJ, Park JY, Bang S, Park SW, Song SY (2014) Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother 63(9):939\u2013946","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2127_CR3","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893\u20132917","journal-title":"Int J Cancer"},{"issue":"Suppl 8","key":"2127_CR4","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","volume":"23","author":"OJ Finn","year":"2012","unstructured":"Finn OJ (2012) Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23(Suppl 8):viii6\u2013viii9","journal-title":"Ann Oncol"},{"key":"2127_CR5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1172\/JCI111794","volume":"75","author":"T Hercend","year":"1985","unstructured":"Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A et al (1985) Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 75:932\u2013943","journal-title":"J Clin Invest"},{"key":"2127_CR6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","volume":"137","author":"C Hontscha","year":"2010","unstructured":"Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2010) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305\u2013310","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2127_CR7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","volume":"137","author":"C Hontscha","year":"2011","unstructured":"Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IGH (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137(2):305\u2013310","journal-title":"J Cancer Res Clin Oncol"},{"key":"2127_CR8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dld.2008.04.007","volume":"41","author":"D Hui","year":"2009","unstructured":"Hui D, Qiang L, Jian W, Ti Z, Da-Lu K (2009) A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41:36\u201341","journal-title":"Dig Liver Dis"},{"key":"2127_CR9","first-page":"322","volume":"20","author":"J Jiang","year":"2005","unstructured":"Jiang J, Wu C, Deng H (2005) Compare cytotoxicity of cytokine induced killer cells with tumor infiltrating lymphocytes in vitro. Lab Med 20:322\u2013324","journal-title":"Lab Med"},{"key":"2127_CR10","first-page":"2237","volume":"26","author":"J Jiang","year":"2006","unstructured":"Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26:2237\u20132242","journal-title":"Anticancer Res"},{"key":"2127_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"2127_CR12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/BF02977372","volume":"30","author":"HM Kim","year":"2007","unstructured":"Kim HM, Kang JS, Lim J, Park SK, Lee K, Yoon YD, Lee CW, Lee KH, Han G, Yang KH, Kim YJ, Kim Y, Han SB (2007) Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30:1464\u20131470","journal-title":"Arch Pharm Res"},{"key":"2127_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbmt.2004.11.019","volume":"11","author":"T Leemhuis","year":"2005","unstructured":"Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181\u2013187","journal-title":"Biol Blood Marrow Transplant"},{"key":"2127_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-014-0215-0","volume":"12","author":"XD Li","year":"2014","unstructured":"Li XD, Ji M, Zheng X, Ning ZH, Wu J, Lu BF, Wu CP, Jiang JT (2014) Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. J Transl Med 12:215\u2013219","journal-title":"J Transl Med"},{"issue":"6","key":"2127_CR15","doi-asserted-by":"crossref","first-page":"e0130620","DOI":"10.1371\/journal.pone.0130620","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, Pan K, Liu L-z, Li Y-q, Mo-fa G, Zhang H, Shen W-x, Xia J-c, Li J-j (2015) Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PLoS ONE 10(6):e0130620","journal-title":"PLoS ONE"},{"issue":"6","key":"2127_CR16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00432-010-0954-0","volume":"137","author":"W Ling","year":"2010","unstructured":"Ling W, Fan J, Yue M, Yuan M, Wang H (2010) Capecitabine-based chemotherapy for metastatic colorectal cancer. J Cancer Res Clin Oncol 137(6):927\u2013938","journal-title":"J Cancer Res Clin Oncol"},{"key":"2127_CR17","doi-asserted-by":"crossref","unstructured":"Linn YC, Hui KM (2010) Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 1\u20138. doi: 10.1155\/2010\/435745","DOI":"10.1155\/2010\/435745"},{"key":"2127_CR18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","volume":"18","author":"L Liu","year":"2012","unstructured":"Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X (2012) Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 18:1751\u20131759","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2127_CR19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2710.2011.01289.x","volume":"37","author":"Y Ma","year":"2012","unstructured":"Ma Y, Tang L, Wang HX et al (2012a) Capecitabine for the treatment of advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther 37(3):266\u2013275","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"2127_CR20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/14653249.2011.649185","volume":"14","author":"Y Ma","year":"2012","unstructured":"Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, Wang HX (2012b) Cytokine-induced killer (CIK) cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14(4):483\u2013493","journal-title":"Cytotherapy"},{"key":"2127_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2162-3619-1-11","volume":"1","author":"Y Ma","year":"2012","unstructured":"Ma Y, Xu YC, Tang L et al (2012c) Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 1:11","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"2127_CR22","first-page":"1029","volume":"86","author":"A M\u00e4rten","year":"2001","unstructured":"M\u00e4rten A, Renoth S, von Lilienfeld-Toal M et al (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86(10):1029\u20131037","journal-title":"Haematologica"},{"issue":"9","key":"2127_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","volume":"2","author":"DM Parkin","year":"2001","unstructured":"Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533\u2013543","journal-title":"Lancet Oncol"},{"key":"2127_CR24","first-page":"595","volume":"75","author":"S Rosenberg","year":"1985","unstructured":"Rosenberg S (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595\u2013603","journal-title":"J Natl Cancer Inst"},{"key":"2127_CR25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318\u20131321","journal-title":"Science"},{"issue":"17","key":"2127_CR26","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"1","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM et al (2011) durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 1(17):4550","journal-title":"Clin Cancer Res"},{"key":"2127_CR27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-13-1559","volume":"74","author":"D Sangiolo","year":"2014","unstructured":"Sangiolo D, Mesiano G, Gammaitoni L et al (2014) Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 74:119","journal-title":"Cancer Res"},{"key":"2127_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139\u2013149","journal-title":"J Exp Med"},{"issue":"6","key":"2127_CR29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","volume":"81","author":"IGH Schmidt-Wolf","year":"1999","unstructured":"Schmidt-Wolf IGH, Finke S, Trojaneck B et al (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-1 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81(6):1009\u20131016","journal-title":"Br J Cancer"},{"issue":"1","key":"2127_CR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330","journal-title":"CA Cancer J Clin"},{"key":"2127_CR31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1126\/science.8451642","volume":"259","author":"H Takahashi","year":"1993","unstructured":"Takahashi H, Nakada T, Puisieux I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259:1460\u20131463","journal-title":"Science"},{"key":"2127_CR32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002620000111","volume":"49","author":"MR Verneris","year":"2000","unstructured":"Verneris MR, Kornacker M, Mailander V, Negrin RS (2000) Resistance of ex vivo expanded CD3+ CD56+ T-cells to Fas mediated apoptosis. Cancer Immunol Immunother 49:335\u2013345","journal-title":"Cancer Immunol Immunother"},{"key":"2127_CR33","first-page":"3997","volume":"28","author":"CP Wu","year":"2008","unstructured":"Wu CP, Jiang JT, Shi LR, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28:3997\u20134002","journal-title":"Anticancer Res"},{"key":"2127_CR34","first-page":"4770","volume":"49","author":"YS Yun","year":"1989","unstructured":"Yun YS, Hargrove ME, Ting CC (1989) In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49:4770\u20134774","journal-title":"Cancer Res"},{"key":"2127_CR35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biopha.2014.12.025","volume":"70","author":"J Zhanga","year":"2015","unstructured":"Zhanga J, Zhua L, Dua H, Heb X, Yina Y, Gua Y, Liua L, Lua K, Guoa R, Liua P, Shu Y (2015) Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study. Biomed Pharmacother 70:248\u2013252","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2127-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2127-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:47:49Z","timestamp":1600267669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2127-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2127-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}